Michael, M; Wirth, A; Ball, DL; MacManus, M; Rischin, D; Mileshkin, L; Solomon, B; McKendrick, J; Milner, AD
(NATURE PUBLISHING GROUP, 2005-09-19)
The role of concurrent chemoradiotherapy (CRT) in patients with non-small-cell lung cancer (NSCLC) unsuitable for radical therapy but who require locoregional treatment has not been defined. The aims of this phase I trial were thus to develop a novel regimen of weekly chemotherapy concurrent with high-dose palliative RT (40 Gy/20 fractions) and assess its tolerability, objective and symptomatic response rates. Eligible patients had stage I-IIIB NSCLC unsuitable for radical RT or limited stage IV disease, ECOG PS